Abstracts / posters
| Product | Conference | Title | Download |
| BI-505 | 53rd ASH Annual Meeting, December 10-13, 2011, San Diego, USA | The effect of ICAM-1 Antibody Therapy in the SCID-Hu Mouse Model Using Primary Myeloma Cells |  |
| TB-402 | 57th Congress of the International Society on Thrombosis and Haemostasis, July 23-27, 2011, Kyoto, Japan | Partial vs complete FVIII inhibition in a mouse model of venous thrombosis | |
| TB-402 | 57th Congress of the International Society on Thrombosis and Haemostasis, July 23-27, 2011, Kyoto, Japan | Effects of a FVIII inhibitor TB-402 on coagulation: reversibility with pro-coagulants | |
| BI-505 | 102nd AACR Annual Meeting, April 2-6, 2011, Orlando, FL, USA | Cell death-inducing ICAM-1 antibody has broad and potent anti-myeloma activity in vivo | |
| BI-505 | 13th International Myeloma Workshop, May 3-6, 2011, Paris, France |
The epitope targeted by cell death-inducing ICAM-1 antibody BI-505 is highly expressed in multiple myeloma |
|
| TB-402 | 21st International Congress on Thrombosis: July 6-9, 2010, Milan, Italy | Single intravenous administration of TB-402 for the prophylaxis of VTE after total knee replacement surgery | |
| TB-403 | AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics in Boston, MA, USA, Nov 09 | A phase I, dose escalation study of TB-403 in patients with solid tumors | |
| TB-403 | AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics in Boston, MA, USA, Nov 09 | A first-in-man, phase I, dose escalation study of TB-403 in healthy male subjects | |
| TB-402 | American Society of Hematology (ASH) 49th Annual Meeting in Atlanta, Georgia, USA, Dec 2007 | A Human Monoclonal Antibody Partially Inhibiting FVIII Activity: A Novel, Long-acting Antithrombotic Drug | |
BioInvent International • SE-223 70 Lund, Sweden • Visiting: Sölvegatan 41, Lund, Sweden • Tel: +46 (0)46-286 85 50 • E-mail: info@bioinvent.com